Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$100.69 -2.1%	$106.75	$72.21 ▼ $139.13	$5.07B	0.47	678,849 shs	1.15 million shs
GKOS Glaukos	$100.32 -2.0%	$93.91	$77.10 ▼ $163.71	$5.85B	0.8	737,565 shs	1.88 million shs
OMCL Omnicell	$28.03 -0.8%	$29.45	$22.66 ▼ $55.75	$1.32B	0.78	576,195 shs	695,716 shs
PTCT PTC Therapeutics	$50.20 -0.5%	$47.95	$28.72 ▼ $58.38	$4.00B	0.51	875,468 shs	3.44 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	0.00%	-3.16%	-5.04%	-18.85%	+35.35%
GKOS Glaukos	0.00%	+5.10%	+4.94%	+0.28%	-9.77%
OMCL Omnicell	0.00%	-5.58%	-1.77%	-16.71%	+2.95%
PTCT PTC Therapeutics	0.00%	-1.08%	+6.84%	-11.74%	+41.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6477 of 5 stars	4.5	2.0	4.5	1.4	4.2	0.6
GKOS Glaukos	4.5121 of 5 stars	4.4	2.0	4.4	2.4	2.5	0.6
OMCL Omnicell	2.4879 of 5 stars	3.3	2.0	0.0	2.1	1.7	1.3
PTCT PTC Therapeutics	4.6356 of 5 stars	4.3	4.0	4.4	2.0	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	71.15% Upside
GKOS Glaukos	2.75	Moderate Buy	$134.67	34.23% Upside
OMCL Omnicell	2.57	Moderate Buy	$44.83	59.95% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	29.48% Upside

Current Analyst Ratings Breakdown

Latest OMCL, PTCT, AXSM, and GKOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/23/2025	OMCL Omnicell	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/23/2025	OMCL Omnicell	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$30.00 ➝ $34.00
5/23/2025	OMCL Omnicell	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$35.00 ➝ $37.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	12.85	N/A	N/A	$1.18 per share	85.33
GKOS Glaukos	$383.48M	14.95	N/A	N/A	$13.91 per share	7.21
OMCL Omnicell	$1.11B	1.18	$3.03 per share	9.24	$26.84 per share	1.04
PTCT PTC Therapeutics	$806.78M	4.93	N/A	N/A	($14.24) per share	-3.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	35.71	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
GKOS Glaukos	-$146.37M	-$2.37	N/A	N/A	N/A	-31.40%	-10.66%	-8.06%	7/30/2025 (Estimated)
OMCL Omnicell	$12.53M	$0.46	60.94	22.60	N/A	1.87%	4.60%	2.56%	7/30/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.71	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)

Latest OMCL, PTCT, AXSM, and GKOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	OMCL Omnicell	$0.16	$0.26	+$0.10	-$0.15	$260.18 million	$269.67 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
4/30/2025	Q1 2025	GKOS Glaukos	-$0.33	-$0.22	+$0.11	-$0.32	$102.78 million	$106.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
OMCL Omnicell	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
GKOS Glaukos	0.09	6.49	5.62
OMCL Omnicell	0.13	1.38	1.23
PTCT PTC Therapeutics	N/A	3.89	3.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
GKOS Glaukos	99.04%
OMCL Omnicell	97.70%
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
GKOS Glaukos	5.80%
OMCL Omnicell	2.52%
PTCT PTC Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
GKOS Glaukos	780	57.14 million	53.83 million	Optionable
OMCL Omnicell	3,670	46.84 million	45.66 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable

OMCL, PTCT, AXSM, and GKOS Headlines

Recent News About These Companies

Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches

June 20 at 10:27 AM | msn.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 19 at 4:30 PM | prnewswire.com

PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Truist Financial

June 19 at 1:43 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 18 at 12:35 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 17 at 10:00 AM | prnewswire.com

Truist Financial Begins Coverage on PTC Therapeutics (NASDAQ:PTCT)

June 17 at 8:43 AM | marketbeat.com

PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

June 16, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 16, 2025 | accessnewswire.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lowered by Assenagon Asset Management S.A.

June 14, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 13, 2025 | accessnewswire.com

Pallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)

June 13, 2025 | marketbeat.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by GAMMA Investing LLC

June 13, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 12, 2025 | prnewswire.com

Harbor Capital Advisors Inc. Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)

June 12, 2025 | marketbeat.com

Analysts Issue Forecasts for PTCT FY2026 Earnings

June 12, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 11, 2025 | accessnewswire.com

Brokers Offer Predictions for PTCT FY2026 Earnings

June 10, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 9, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 7, 2025 | prnewswire.com

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy

June 6, 2025 | zacks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL, PTCT, AXSM, and GKOS Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$100.69 -2.20 (-2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$105.40 +4.71 (+4.68%)

As of 05:12 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Glaukos NYSE:GKOS

$100.32 -2.02 (-1.97%)

Closing price 03:59 PM Eastern

Extended Trading

$100.14 -0.18 (-0.18%)

As of 06:09 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Omnicell NASDAQ:OMCL

$28.03 -0.24 (-0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$28.04 +0.00 (+0.02%)

As of 06:15 PM Eastern

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

PTC Therapeutics NASDAQ:PTCT

$50.20 -0.23 (-0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$50.20 0.00 (0.00%)

As of 06:37 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time